Hydroxyzine
This first-generation antihistamine has anxiolytic, antipruritic, and sedative properties and is used to treat anxiety, itching from allergic conditions, and nausea. It works by blocking histamine H1 receptors and also affects other neurotransmitter systems in the brain. It does not carry the risk of dependence seen with benzodiazepines.
분자량
374.9000 g/mol
LogP
3.70
TPSA
35.90 Ų
리핀스키 5의 법칙
통과
치료 영역
작용 기전
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …
2D 구조
Cite this structure
Embed this structure
SMILES
OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
InChI
InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2
Molecular Formula
C21H27ClN2O2
HBD / HBA
1 / 4
회전 가능 결합
8
무거운 원자
26
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
This first-generation antihistamine has anxiolytic, antipruritic, and sedative properties and is used to treat anxiety, itching from allergic conditions, and nausea. It works by blocking histamine H1 receptors and also affects other neurotransmitter systems in the brain. It does not carry the risk of dependence seen with benzodiazepines.
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.
Yes, Hydroxyzine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL896. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3658. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="hydroxyzine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/hydroxyzine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/hydroxyzine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/hydroxyzine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="hydroxyzine"></drugfyi-drug>